mRNA Flu Shot Candidate Announces Positive Results

Massachusetts-based Moderna, Inc. today announced the first positive interim data from the Phase 1 study of the Company's quadrivalent seasonal influenza vaccine candidate, mRNA-1010.

In the Phase 1 study, mRNA-1010 was evaluated at 50 µg, 100 µg, and 200 µg dose levels in younger adult (age 18-49) and older adult (age 50+) cohorts.

In the study, mRNA-1010 successfully boosted hemagglutination inhibition (HAI) assay geometric mean titers against all strains 29 days after vaccination at all doses tested in both younger and older adults.

The Company also announced that the Phase 2 study of mRNA-1010 is now fully enrolled, and the preparation for the Phase 3 study is underway.

"Even before the COVID-19 pandemic, approximately three million people died each year due to respiratory infections, and many more are hospitalized or become ill as a result of these viruses. At Moderna, our goal is to limit this suffering with an annual pan-respiratory single-dose booster vaccine that is adapted to the circulating strains of SARS-CoV-2, seasonal influenza, and RSV," said Stéphane Bancel, CEO of Moderna, in a press release issued on December 10, 2021.

"The positive interim results from our Phase 1 quadrivalent flu vaccine candidate, mRNA-1010, are an important milestone toward achieving that goal."

Quadrivalent mRNA-1010 encodes for the hemagglutinin protein from four seasonal influenza viruses based on the recommendations of the World Health Organization (WHO), including seasonal influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.